Today on Outsourcing-Pharma.com   New counterfeit report highlights worrying trends PharmaNet makes a Q3 comeback DSM third quarter results Preclinical services news in brief New firm to tackle poor solubility head on

Related Industry News   Merck flexes muscle with GTx deal New safety warning delays Novartis diabetes drug Apitope vaccine stops MS in its tracks Pretender to Avastin throne poised to enter clinical trails

Breaking News on Outsourcing Pharma
Daily  Wednesday 07 November 2007		Forward to a colleague

	Company Profile DPT - The Industry Source for Semi-solids and Liquids. DPT is a contract development and manufacturing organization (CDMO) specializing in semi-solid and liquid dosage forms providing solutions from concept to commercialization. Click here to learn more about our services... Click Here Access Full Stories New counterfeit report highlights worrying trends A new report highlights a number of worrying trends emerging in regard to the increasing number of fake pharmaceuticals infiltrating supply chains around the globe... Read PharmaNet makes a Q3 comeback PharmaNet has made a strong comeback during its third quarter after previously slipping into the red and recorded its highest revenue to date - $99.8m (€70.0m)... Read DSM third quarter results DSM's third quarter financial results are paving the way for the company's transition to a life sciences and material sciences company... Read Preclinical services news in brief In this week's review of activity within the preclinical research services arena, new deals have emerged involving MDS Pharma Services, Bruker Biospin and Expression Analysis... Read New firm to tackle poor solubility head on A new Belgian company has joined the throng of pharmas tapping into the booming drug delivery business, but claims that its unique technologies will carve it a place as one of the industry's key players... Read
	All News Headlines for: November | October | September
	Related Industry News Merck flexes muscle with GTx deal Merck & Co has inked a deal potentially worth over €507m (€346m) with GTx over a new class of drugs to treat muscle loss conditions, especially those caused by cancer... Read New safety warning delays Novartis diabetes drug Swiss firm Novartis today announced that it has contacted regulators regarding the safety of the 100mg dose of its recently approved Type II diabetes drug, Galvus (vildagliptin)... Read Apitope vaccine stops MS in its tracks UK biopharmaceutical firm Apitope has developed a vaccine that could halt multiple sclerosis in its relentless march to destroy nerve cells... Read Pretender to Avastin throne poised to enter clinical trails BioInvent and ThromboGenics' new anticancer antibody is poised to enter clinical trials and could prove a serious rival to VEGF-blocking drugs, due to fewer side-effects and less drug resistance... Read Weekly Comment Big pharma lends a helping hand Despite often attracting a barrage of negative publicity, particularly in regard to a perception of putting profits before people, big pharma firms are still capable of showing their human side in times of crisis. Read Previous Headlines Contract manufacturing news in brief Bioserv Corporation, Mikart, Laureate Pharma, Cenexi and Lonza have all recently announced new contract manufacturing news... Read Charles River sails through Q3 Charles River Laboratories sailed through its third quarter, with comfortable gains in both revenue and profits... Read Icon improves its position, Kendle slips again Icon has improved its financial position significantly during its third quarter, while its smaller US rival Kendle saw its profit slip again, weighed down by charges from a 2006 acquisition... Read EU considers Afghan poppy pilot A proposed pilot programme to divert Afghanistan's infamous and illegal opium supply for legal use in analgesics has been backed by the European Parliament but is facing fierce criticism elsewhere... Read FDA failure on foreign inspections frightening A US government audit has confirmed the Food and Drug Administration's (FDA's) continual lack of inspection of foreign drug manufacturing plants... Read Technical / White Papers, Case studies, Web casts Benefits of integrating human tissue research in drug discovery - Technical / White Paper Product Innovation Alerts - Free of Charge Indicate your research interests and receive alerts on relevant products and market innovations Analytical testing, QC Bulk ingredients Contract sales & marketing Data management Drug delivery, formulation Fill & finish, packaging Phase I-II Phase III-IV Preclinical Product & Supplier News - Contract Manufacturing Regulatory affairs Supply chain, logistics Validation services

	Free Newsletters for Pharmaceuticals Access now !Choose from over 20 industry e-newsletters Access Decision News Media e-newsletters for the food, beverage & nutrition industries, click here
	Forward to a colleague

	To continue to receive this newsletter in your inbox, please add newsletter@OutSourcing-Pharma.com to your address book
	Update preferences | Change your email address | Unsubscribe
	Contact us: Advertising | Recruitment | Privacy policy | Terms & conditions | Feedback
	© 2007 - Decision News Media S.A.S - All Rights Reserved Le Belem - 355, rue Vendemiaire - 34000 Montpellier - France http://www.decisionnewsmedia.com